Mylan, Other Drugmakers Must Pay $67M In Antitrust Suit

By Kelly Knaub (August 31, 2017, 4:56 PM EDT) -- The D.C. federal court has ordered generic-drug maker Mylan Pharmaceuticals and chemical companies Cambrex and Gyma Laboratories to pay a combined $67 million to Blue Cross Blue Shield of Massachusetts and three other insurers in a long-running suit accusing the three companies of violating state antitrust laws.

U.S. District Judge Thomas F. Hogan granted a bid by BCBS of Massachusetts, Blue Cross Blue Shield of Minnesota, Federated Insurance Co. and Health Care Service Corp. to adjust the previous $76 million judgment to roughly $67 million on Aug. 18, more than three years after granting their bid to dismiss certain plaintiffs from the...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!